Overview
MVL provides genetic testing for inherited eye diseases to clinicians, researchers, and patients worldwide. Its main test, the MVL Vision Panel, uses high-coverage next-generation sequencing to analyze 1,251 genes related to retinal dystrophies and other eye conditions, with all variants confirmed by Sanger sequencing and free parental testing to validate results. The company differentiates itself through its ophthalmic genetics focus, a large proprietary sequencing database that supports its bioinformatics pipeline, CAP/CLIA certification, and its role as a partner for clinical trials, patient care, and research, with prices set as out-of-pocket rather than billing insurance. Its goal is to provide comprehensive, accessible diagnostic testing and support for clinical studies in vision-related genetics.
Work here?Claim your company
Simplify's take
What believers are saying
- MVL updated its website in October 2026, signaling active operations and commercial upkeep.
- New York permit runs through June 30, 2027, confirming current regulatory clearance.
- Open hiring in 2026 suggests ongoing demand for NGS and laboratory operations.
What critics are saying
- CAP accreditation expires November 28, 2026, threatening continuity if renewal slips.
- MVL sells self-pay testing only, limiting adoption when clinicians need reimbursed diagnostics.
- GeneDx, Blueprint Genetics, and Prevention Genetics can undercut MVL's niche by scale.
What makes Molecular Vision Laboratory unique
- Only CAP/CLIA ophthalmic genetics reference lab, focused on inherited retinal diseases.
- MVL Vision Panel covers 1,251 genes, with Sanger confirmation and free parental testing.
- Proprietary retinal dystrophy database and OHSU roots deepen interpretation and clinical-trial utility.
Help us improve and share your feedback! Did you find this helpful?